Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Sobi® today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a p...
AbbVie's Upadacitinib outperforms dupilumab in Phase 3b/4 study for atopic dermatitis treatment, achieving superior efficac...
Sanofi reports Q1 operating income at 2.8 billion euros, down 14.7%. Beat consensus EPS at $0.97. Sales reach $11.36 billion, l...
The back-and-forth motion in the market continues, with the index futures pointing to a lower opening on Thursday. Meta Platfor...
Business EPS guidance reiterated Sanofi expects 2024 business EPS(1) to remain roughly stable excluding the impact of an expec...
Sanofi (NASDAQ:SNY) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.94 by 2.77 p...
Rilzabrutinib LUNA 3 phase 3 study met primary endpoint in immune thrombocytopenia Pivotal data from the first phase 3 study...
- Bloomberg
